TRexBio Prices IPO at $14.00 Per Share to Raise $116.7 Million

Key Facts

TRexBio announced the pricing of its initial public offering of 8,333,334 shares of common stock at $14.00 per share. GlobeNewswire reported that the company expects to raise approximately $116.7 million in gross proceeds before expenses, with shares scheduled to begin trading on the Nasdaq Global Select Market under the ticker TRXB on October 9, 2026.

The clinical-stage biotechnology firm intends to use the capital to fund the development of immunoregulatory medicines through its tissue biology platform. Meanwhile, NDAQ, the operator of the exchange where the stock will list, closed at $92.37 on October 8, 2026, having traded between a low of $91.1 and a high of $92.69 during that session.